Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD/MAD of TBAJ-587 in Healthy Adults
NCT04890535Phase 1Completed
- Sponsor
- TB Alliance
- Start
- Dec 2020
- Primary completion
- Feb 2023
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of TBAJ-587 in Tuberculosis (TB) (4 arms), sponsored by TB Alliance. Primary endpoints: Number of Participants with Treatment-Related Adverse Events in the Single Ascending Dose (SAD) population at Day 126 and Number of Participants with Treatment-Related Adverse Events in the Multiple Ascending Dose (MAD) population at Day 168. Started Dec 2020; status: completed.
02
Drugs
TBAJ-587
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT04890535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04890535.